Agomab Therapeutics

Agomab Therapeutics is a clinical-stage biotechnology company focused on developing novel treatments to preserve and restore organ function in fibrotic diseases. The company leverages deep expertise in growth factor biology to target two key signaling pathways involved in fibrosis: Transforming Growth Factor beta (TGFβ) and Hepatocyte Growth Factor (HGF). Agomab utilizes specialized capabilities in organ-restricted small molecules and high-affinity antibodies to minimize systemic side effects while maximizing therapeutic impact at the site of disease. Their lead programs address high unmet needs in fibrostenosing Crohn’s disease, idiopathic pulmonary fibrosis, and liver cirrhosis.